A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants
Condition: Healthy Volunteers Intervention: Drug: HYQVIA Sponsors: Baxalta now part of Shire; Baxalta Innovations GmbH, now part of Shire Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 8, 2020 Category: Research Source Type: clinical trials
